Sorafenib
Sorafenib is a pharmaceutical drug with 361 clinical trials. Currently 31 active trials ongoing. Historical success rate of 76.5%.
Success Metrics
Based on 192 completed trials
Phase Distribution
Phase Distribution
123
Early Stage
151
Mid Stage
57
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
70.8%
192 of 271 finished
29.2%
79 ended early
31
trials recruiting
361
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
Clinical Trials (361)
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 361